Current Cardiology Reports

, 13:553 | Cite as

Predictors of Statin Adherence

Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor)

Abstract

Statin therapy plays a central role in decreasing the morbidity and mortality associated with cardiovascular disease. However, prescribed statins are only effective if they are taken by patients on a regular basis, known as medication adherence. The factors that influence patient adherence to statin therapy can be categorized into patient factors, physician factors, and health system factors, often with interactions between the categories. Patient factors include demographics, socioeconomic status, comorbidities, and side effects. Physician factors include the physician’s own adherence to applying guideline recommendations, office visits, and their interactions with patients. Health system factors include issues such as cost and access to care. Physicians should be aware of the various elements that may influence a patient’s likelihood to take statin medications to improve adherence and provide the best possible patient outcomes.

Keywords

Statin Adherence Cardiovascular disease Coronary artery disease Patient factors Physician factors Health system factors Socioeconomic 

Clinical Trial Acronyms

IDEAL

Incremental Decrease in End Points Through Aggressive Lipid Lowering

MIRACL

Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering

NCEP ATP III

National Cholesterol Education Program Adult Treatment Panel III

NHANES

National Health and Nutrition Examination Survey

PREMIER

Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery

PROVE-IT-TIMI 22

Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22

TNT

Treating to New Targets

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag. 2010;6:843–53.PubMedGoogle Scholar
  2. 2.
    Weart CW, Hogan RJ. Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy. Expert Opin Pharmacother. 2011;12(1):99–117.PubMedCrossRefGoogle Scholar
  3. 3.
    Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Osterberg L, Blaschke T. Adherence to medication. NEJM. 2005;353(5):487–97.PubMedCrossRefGoogle Scholar
  5. 5.
    Lutfey KE, Wishner WJ. Beyond “compliance” is “adherence”. Improving the prospect of diabetes care. Diabetes Care. 1999;22(4):635–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol. 2010;56(25):e50–103.PubMedCrossRefGoogle Scholar
  7. 7.
    Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104:365–72.PubMedGoogle Scholar
  8. 8.
    MMWR Morb Mortal Wkly Rep. 2011;60(4):109–14. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol–United States, 1999–2002 and 2005–2008Google Scholar
  9. 9.
    Gotto Jr AM, LaRosa JC, Hunninghake D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81:1721–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383–9.Google Scholar
  11. 11.
    Bersot TP: Chapter 31. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman and Gilman: The pharmacological basis of therapeutics,12e.McGraw-Hill. 2011.Google Scholar
  12. 12.
    Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev. 2010;18(6):298–304.PubMedCrossRefGoogle Scholar
  13. 13.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  14. 14.
    Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002;106(13):1690–5.PubMedCrossRefGoogle Scholar
  15. 15.
    LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.PubMedCrossRefGoogle Scholar
  16. 16.
    Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the ideal study: a randomized controlled trial. JAMA. 2005;294:2437–45.PubMedCrossRefGoogle Scholar
  17. 17.
    Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  18. 18.
    Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.PubMedCrossRefGoogle Scholar
  21. 21.
    Ye X, Gross CR, Schommer J, et al. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748–57.PubMedCrossRefGoogle Scholar
  22. 22.
    Chan DC, Shrank WH, Cutler D. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196–202.PubMedCrossRefGoogle Scholar
  23. 23.
    •• Traylor AH, Schmittdiel JA, Uratsu CS, et al. Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med. 2010;25(11):1172–7. When examining the impact of similarities between patients and their physicians, this study demonstrated that African Americans had improved adherence when their physician was also African American. Spanish-speaking patients had similar improved adherence when their physician also spoke Spanish.PubMedCrossRefGoogle Scholar
  24. 24.
    Rasmussen JN, Gislason GH, Rasmussen S, et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health. 2007;61(12):1091–7.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25(7):850–5. Adherence to statin therapy is highest amongst those diabetic patients who have additional cardiovascular comorbidity.PubMedCrossRefGoogle Scholar
  26. 26.
    Pittman DG, Chen W, Bowlin SJ, et al. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107(11):1662–6.PubMedCrossRefGoogle Scholar
  27. 27.
    •• Kulik A, Shrank WH, Levin R, et al.: Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107(10):1409–14. In patients who receive coronary revascularization compared to those who are treated with medicines alone, adherence is higher among patients treated with medicines alone. This identifies the need for greater attention to adherence among patients who undergo coronary revascularization.PubMedCrossRefGoogle Scholar
  28. 28.
    Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen SM, Kataoka-Yahiro M. Provider adherence to clinical guidelines related to lipid-lowering medications. Mil Med. 2010;175(2):122–6.PubMedGoogle Scholar
  30. 30.
    Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882–89.PubMedCrossRefGoogle Scholar
  31. 31.
    Brookhart MA, Patrick AR, Schneeweiss S. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847–52.PubMedCrossRefGoogle Scholar
  32. 32.
    •• Daugherty SL, Ho PM, Spertus JA, et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med. 2008;168(5):485–91; discussion 492. Patient follow-up with their physicians early after an MI plays an important role in improving statin adherence. In particular, statin use is best adhered to when the patient follows up with both the primary care physician and the cardiologist.Google Scholar
  33. 33.
    Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no.:SP11-9.Google Scholar
  34. 34.
    •• Helin-Salmivaara A, Korhonen MJ, Alanen T, et al. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. J Clin Pharm Ther. 2011 Mar 16. Lower out-of-pocket expenses for statins are associated with improved adherence.Google Scholar
  35. 35.
    Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638–45.PubMedCrossRefGoogle Scholar
  36. 36.
    Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med. 2007;167(16):1798–803.PubMedCrossRefGoogle Scholar
  37. 37.
    Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27(12):2800–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of CardiologyNew York Presbyterian Hospital–Weill Cornell Medical CenterNew YorkUSA
  2. 2.Division of CardiologyNew York Presbyterian Hospital–Weill Cornell Medical CenterNew YorkUSA

Personalised recommendations